Oxford BioMedica (OXB); study of AXO-Lenti-PD by Axovant administers first dose to patient
Stock down 1.70% to 671.90p at 8:22
Oxford BioMedica reported that the gene therapy AXO-Lenti-PD, outlicensed to Axovant in June 2018, has been administered to the first patient. The aim of the ongoing clinical study is to evaluate safety and tolerability and collect efficacy data, including standard measures of motor function in patients with Parkinson’s disease.
Read more...Air Partner (AIR); half year results deliver solid first half trading
Stock flat at 106.50p at 08:07
The core business has performed positively with PBT up 2.4% to £4.2m and gross profit close to last year at £18.0m. Commercial Jets, the core division, was buoyed by the World Cup and tour operators partially compensating for the absence of a one-off contract in the prior year, but ended with gross profit down 11% at £8.4m.
Read more...StatPro Group (SOG); revenue and profits remain in line with FY18 expectations
Annualised recurring revenue grew 3% for the year to £54.8m
The company announced its trading update for the nine months ended 30 September 2018. The company anticipates the Infovest division to contribute positively to its profits and make steady progress, aided by the recent contract win with a large South African financial institution.
Read more...ANGLE (AGL); over 75% of subject enrolment for clinical study complete
Clinical study expected to the be complete by Q1 CY 2019
ANGLE reported it has enrolled over 75% of the required 200 metastatic breast cancer patients and 200 healthy volunteers of a similar age and demographic for its ANG-002 FDA clinical study.
Read more...Cohort (CHRT); selected as preferred bidder for a £50m MOD contract
Cohort's subsidiary, MASS, to provide in-service support to the MOD
Cohort announced that its wholly owned subsidiary, MASS Consultants, has been selected as the preferred bidder for an eight-year contract valued at over £50m
Read more...Polypipe (PLP); acquisition of Manthorpe Building Products a strategic fit
Aquisition expected to be EPS accretive
Polypipe announced the acquisition of Manthorpe Building Products for a total cash consideration of £52m on a cash and debt free, normalised working capital basis, including associated freehold land and buildings.
Read more...
VinaCapital Vietnam Opportunity Fund (VOF); grew net assets by 13.7%
VinaCapital Vietnam Opportunity Fund recently joined the FTSE 250 index
VinaCapital Vietnam Opportunity Fund (VOF) grew its net assets by 13.7% in the financial year ended 30 June 2018, with dividends bringing the NAV total return to 16.7% in US dollar terms. While this was below the return of the headline Vietnam VN index, VOF’s capital markets portfolio (which also holds private equity and real estate investments) outperformed the index by c 7pp. Dividends for the year totalled c 2% of NAV.
Read more...Target Healthcare REIT (THRL); proposed issue of equity
Offer price represents a premium of 2.7% to the last reported EPRA NAV of 106.1p/sh
Target Healthcare REIT proposed to raise £40m through the issuance of 36,697,248 placing shares at 109p/sh, a non-pre-emptive placing under its existing placing programme.
Read more...Stobart (STOB); interim results; strong growth in revenue and underlying EBITDA
The company noted accelerating passenger growth in London's Southend Airport
The company noted in its interim that both Stobart Aviation and Stobart Energy are well-invested and set for significant growth. Group pro forma underlying EBITDA grew to £24.4m; Aviation +14.6% to £15.7m and Energy +88.8% to £8.7m. Loss for the period after taxation was at £17.5m.
Read more...Competition and Markets Authority swings the odds strongly in favour of the Sainsbury/Asda merger
Issues Statement concedes that the presence of Aldi and Lidl stores will be taken into account when assessing Sainsbury and Asda stores in the same local area
On Thursday the Competition and Markets Authority (CMA) published its Issues Statement explaining how it intends to go about its detailed phase 2 investigation into Sainsbury and Asda’s merger, which is due to report by early March 2019. It did so after agreeing in September to requests from both Sainsbury and Asda to make a ‘fast-track’ phase 1 decision.
Read more...